Search results
Results from the WOW.Com Content Network
MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118 (2007), was a decision by the Supreme Court of the United States involving patent law. [1] It arose from a lawsuit filed by MedImmune which challenged one of the Cabilly patents issued to Genentech.
WASHINGTON (Reuters) -A U.S. appeals court on Monday threw out a $2.18 billion patent-infringement award won by patent owner VLSI Technology against Intel Corp, overturning one of the largest ...
This is a list of notable patent law cases in the United States in chronological order. The cases have been decided notably by the United States Supreme Court, the United States Court of Appeals for the Federal Circuit (CAFC) or the Board of Patent Appeals and Interferences (BPAI). While the Federal Circuit (CAFC) sits below the Supreme Court ...
In response, Nautilus asked the United States Patent and Trademark Office to reexamine the '753 patent to determine whether it had been properly issued. [2] The Patent Office subsequently agreed to conduct the reexamination and the parties voluntarily dismissed the district court suit pending the outcome of the reexamination. [2]
Stanford University v. Roche Molecular Systems, Inc., 563 U.S. 776 (2011), was a United States Supreme Court case in which the Court held that title in a patented invention vests first in the inventor, even if the inventor is a researcher at a federally funded lab subject to the 1980 Bayh–Dole Act. [1]
Kimble v. Marvel Entertainment, LLC, 576 U.S. 446 (2015), is a significant decision of the United States Supreme Court for several reasons. One is that the Court turned back a considerable amount of academic criticism of both the patent misuse doctrine as developed by the Supreme Court and the particular legal principle at issue in the case.
Kappos v. Hyatt, 566 U.S. 431 (2012), was a case decided by the Supreme Court of the United States that held that there are no limitations on a plaintiff's ability to introduce new evidence in a §145 proceeding other than those in the Federal Rules of Evidence and the Federal Rules of Civil Procedure.
United States v. Glaxo Group Ltd., 410 U.S. 52 (1973), [1] is a 1973 decision of the United States Supreme Court in which the Court held that (1) when a patent is directly involved in an antitrust violation, the Government may challenge the validity of the patent; [2] and (2) ordinarily, in patent-antitrust cases, "[m]andatory selling on specified terms and compulsory patent licensing at ...